Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Neurology · Primary Familial Brain Calcification

Standard of Care and Assembling Your Team

At a Glance

Primary familial brain calcification has no available treatment that removes or reverses existing brain calcium. Care is personalized and symptom-focused, using specialists and rehabilitation to manage movement, mood, thinking, swallowing, balance, and daily function.

Managing Primary Familial Brain Calcification (PFBC) requires a shift in perspective: while a brain scan shows the presence of calcium, medical care focuses entirely on the person, not the “spots” [1][2]. It is important to understand that there are currently no “disease-modifying” treatments—medications that can stop, reverse, or “chelate” (remove) the calcium deposits once they have formed [1][2]. Instead, the standard of care is built around symptom-directed management, where each challenge is treated individually to improve your quality of life [1][3].

Building Your Multidisciplinary Team

Because PFBC can affect movement, mood, and thinking, a team-based approach is helpful, but the team is assembled according to your symptoms and needs; an asymptomatic person may not need several specialists [3][2]. Your care team may include:

  • Neurologist (Movement Disorder Specialist): The lead for managing motor symptoms like stiffness or tremors [4][5].
  • Psychiatrist or Neuropsychiatrist: To help manage mood changes, anxiety, or psychosis [6][7].
  • Endocrinologist: To monitor mineral levels (calcium and phosphate) and rule out secondary metabolic issues [8][3].
  • Rehabilitation Therapists: Including Physical Therapists (for balance and gait), Occupational Therapists (for daily living tasks), and Speech-Language Pathologists (for speech and swallowing) [9][10].
  • Genetic Counselor: To discuss family risks and the implications of genetic test results [11][12].

Managing Movement Symptoms

If you experience movement challenges, your neurologist will likely use medication classes common in other movement disorders, adjusted for your specific needs [4][10]. Seizures, dysphagia (swallowing trouble), orthostatic symptoms, constipation, sleep problems, and headaches may need separate evaluation and standard treatments.

  • Parkinsonism: For symptoms like slowness and stiffness, doctors may try dopaminergic medications (such as levodopa) [4]. While some patients see improvement, others may have a limited response, and medications must be started at low doses to monitor for side effects [4].
  • Dystonia and Chorea: Treatment options depend on the specific movement disorder and specialist assessment, and may include rehabilitation, botulinum toxin injections, or other medicines when appropriate [10].
  • Gait and Balance: These are often best managed through physical therapy, gait training, and the use of assistive devices (like canes or walkers) to prevent falls [10][9].

Addressing Mental Health and Cognition

Psychiatric and cognitive symptoms are a significant part of PFBC for many people and deserve proactive care [7][6].

  • Mood and Anxiety: Standard antidepressants (like SSRIs) or anti-anxiety medications are frequently used with success [7].
  • Psychosis: Hallucinations, delusions, or severe behavioral change need prompt clinical assessment [6]. Crucially, all antipsychotic medications can cause or worsen motor adverse effects (such as rigidity, tremor, and parkinsonism). Treatment requires urgent, individualized specialist assessment by psychiatry and/or a movement-disorder neurologist, and there is no preferred drug that is universally safe for a person with a movement disorder [13].
  • Cognitive Support: While there is no specific drug for PFBC-related memory issues, management includes structured routines, cognitive exercises, and treating underlying issues like poor sleep that can make “brain fog” worse [7][14].

The Role of Future Research

The 2025 international consensus guidelines emphasize that while we cannot yet remove brain calcium, active research is underway [2]. Scientists are exploring experimental approaches, like gene-targeted therapies (antisense oligonucleotides) and phosphate-stabilizing methods [15][16]. These are experimental and should not be interpreted as available treatments. Participating in research registries or clinical trials can be a way to contribute to future breakthroughs [NCT01793168][NCT05662111].

Common questions in this guide

Is there a treatment that removes brain calcium in PFBC?
No treatment is currently available to stop, reverse, or remove calcium deposits once they have formed. Doctors instead treat symptoms individually and aim to improve safety, function, and quality of life.
Which specialists might I need for PFBC?
A neurologist, often with movement-disorder expertise, can coordinate care for stiffness, tremor, and other movement symptoms. Depending on your needs, a psychiatrist or neuropsychiatrist, endocrinologist, physical or occupational therapist, speech-language pathologist, or genetic counselor may join. The team should match your symptoms, so someone without symptoms may not need every specialist.
Can levodopa improve movement problems caused by PFBC?
Doctors may try levodopa for slowness and stiffness, but the response varies and some people have little benefit. It is usually started at a low dose so the care team can watch for side effects and adjust treatment safely.
How can PFBC mood or psychosis be treated without worsening movement symptoms?
Standard antidepressants or anti-anxiety medicines may help mood and anxiety. Hallucinations, delusions, or major behavior changes need prompt assessment because any antipsychotic medicine can worsen rigidity, tremor, or parkinsonism. A psychiatrist and movement-disorder neurologist should individualize the plan; no single drug is universally safe for everyone with movement symptoms.
What rehabilitation can help with PFBC balance, daily tasks, speech, or swallowing?
Physical therapy can address balance and walking through gait training, and canes or walkers may reduce fall risk. Occupational therapy can support daily tasks, while a speech-language pathologist can help with speech and swallowing problems.
Are research studies or clinical trials available for PFBC?
Researchers are studying gene-targeted treatments and approaches that stabilize phosphate, but these remain experimental and are not established treatments. Research registries and clinical trials may offer ways to contribute, and your care team can help identify studies for which you may be eligible.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Bilateral striopallidodentate calcinosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my current symptoms, which specialists (like a movement disorder neurologist or a psychiatrist) should be on my core care team?
  2. 2.Is a trial of dopaminergic medication appropriate for my motor symptoms, and what side effects should we monitor for?
  3. 3.How often should I have follow-up visits to reassess my symptoms, even if my brain scan hasn't changed?
  4. 4.Can you recommend a physical or occupational therapist who has experience with rare movement disorders or gait issues?
  5. 5.Are there any specific clinical trials or research registries for PFBC that I might be eligible for?
  6. 6.How do we balance treating my psychiatric or mood symptoms without worsening any movement challenges I have?

References

References (16)
  1. 1

    The clinical and genetic spectrum of primary familial brain calcification.

    Carecchio M, Mainardi M, Bonato G

    Journal of neurology 2023; (270(6)):3270-3277 doi:10.1007/s00415-023-11650-0.

    PMID: 36862146
  2. 2

    Primary Brain Calcification: An International Consensus on Nomenclature, Diagnosis, Evaluation, and Management.

    Luo W, Cen Z, Koek H, et al.

    Movement disorders : official journal of the Movement Disorder Society 2026; (41(2)):315-336 doi:10.1002/mds.70140.

    PMID: 41346103
  3. 3

    White matter disorders with cerebral calcification in adulthood.

    Chelban V, Houlden H

    Handbook of clinical neurology 2024; (204()):111-131 doi:10.1016/B978-0-323-99209-1.00024-7.

    PMID: 39322374
  4. 4

    Primary familial brain calcification presenting with parkinsonism and motor complications caused by a novel SLC20A2 variant: a case report.

    Sun D, Wang Y, Wang J, et al.

    Frontiers in neurology 2024; (15()):1382534 doi:10.3389/fneur.2024.1382534.

    PMID: 39036637
  5. 5

    Genotype-Phenotype Relations in Primary Familial Brain Calcification: Systematic MDSGene Review.

    Balck A, Schaake S, Kuhnke NS, et al.

    Movement disorders : official journal of the Movement Disorder Society 2021; (36(11)):2468-2480 doi:10.1002/mds.28753.

    PMID: 34432325
  6. 6

    SLC20A2-Associated Idiopathic Basal Ganglia Calcification-Related Recurrent Psychosis Response to Low-Dose Antipsychotics: A Case Report and Literature Review.

    Uno A, Tamune H, Kurita H, et al.

    Cureus 2020; (12(12)):e12407 doi:10.7759/cureus.12407.

    PMID: 33532164
  7. 7

    Non-Motor Symptoms in Primary Familial Brain Calcification.

    Bonato G, Cimino P, Pistonesi F, et al.

    Journal of clinical medicine 2024; (13(13)) doi:10.3390/jcm13133873.

    PMID: 38999439
  8. 8

    Basal Ganglia Calcifications for Nephrologists: Fahr/Primary Familial Brain Calcification (PFBC) at the Interface of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) and Hypoparathyroidism.

    Alrashidi FS

    Cureus 2025; (17(12)):e99031 doi:10.7759/cureus.99031.

    PMID: 41531582
  9. 9

    Primary familial brain calcification in a patient with a novel compound heterozygous mutation in MYORG presenting with an acute ischemic stroke: a case report.

    Yang Q, Li J, Jiao B, Weng L

    Annals of translational medicine 2022; (10(7)):423 doi:10.21037/atm-21-4883.

    PMID: 35530931
  10. 10

    The Association between Intracranial Calcifications and Symptoms in Patients with Primary Familial Brain Calcification.

    Mathijssen G, van Valen E, de Jong PA, et al.

    Journal of clinical medicine 2024; (13(3)) doi:10.3390/jcm13030828.

    PMID: 38337525
  11. 11

    Basal ganglia calcification: 'Fahr's disease'.

    Magrinelli F, Jesuthasan A, Bhatia KP, Batla A

    Practical neurology 2025; (25(6)):520-526 doi:10.1136/pn-2024-004258.

    PMID: 40169250
  12. 12

    Novel likely pathogenic SLC20A variant in primary familial brain calcification.

    Sharma R, Stitt D

    BMJ case reports 2022; (15(3)) doi:10.1136/bcr-2021-245909.

    PMID: 35236675
  13. 13

    Bilateral strio-pallido-dentate calcinosis (Fahr's disease): report of seven cases and revision of literature.

    Savino E, Soavi C, Capatti E, et al.

    BMC neurology 2016; (16()):165 doi:10.1186/s12883-016-0693-1.

    PMID: 27608765
  14. 14

    CT-based Volume Measurement of Brain Calcification Is Related to Clinical Symptoms and Disease Progression in Primary Familial Brain Calcification.

    Snijders BMG, Pierey L, Peters MJL, et al.

    Clinical neuroradiology 2026; (36(2)):431-438 doi:10.1007/s00062-025-01595-4.

    PMID: 41296026
  15. 15

    Antisense oligonucleotides enhance SLC20A2 expression and suppress brain calcification in a humanized mouse model.

    Zhao M, Cheng X, Chen L, et al.

    Neuron 2024; (112(19)):3278-3294.e7 doi:10.1016/j.neuron.2024.07.013.

    PMID: 39121859
  16. 16

    Astrocytes modulate brain phosphate homeostasis via polarized distribution of phosphate uptake transporter PiT2 and exporter XPR1.

    Cheng X, Zhao M, Chen L, et al.

    Neuron 2024; (112(18)):3126-3142.e8 doi:10.1016/j.neuron.2024.06.020.

    PMID: 39019040

This page explains symptom-focused care for primary familial brain calcification for informational purposes only and does not constitute medical advice. Your neurologist and other specialists can tailor treatment to your symptoms and medication risks.